MI-PP
Modelling, ImmunoProfiling and Pharmacology Platform
Heads:
Dr. Frédéric Vely; Pr Joseph Ciccolini
Objectives
To empower academic, clinical, and industrial innovators with comprehensive immune monitoring solutions that accelerate breakthroughs in immuno-oncology. Offering customized biomarker testing and analytical services to accelerate therapeutic innovation and precision medicine.
Operator (s)
Technology and expertises
Immunoprofiling of immune cells in tumors by cytometry and single cell RNA transcriptomics analyses.
Functional characterization of immune cell activities in tumor microenvironment.
PK/PD of mAb therapies with mass spectrometry and computational analysis.
Services and activities
Immunoprofiling (cellular immunophenotyping)
BD A8 spectral flow cytometer, BD Fortessa X20 flow cytometer, BD Melody cell sorter.
Functional assays on tissue-derived or blood cell populations
T cell proliferation, NK cell degranulation, NK cell cytotoxicity, Single cell transcriptomic analysis (BD Rhapsody).
Quantification of soluble molecules/cellular markers of activation, proliferation, regulation
ELLA platform (Biotechne), ELISA platform (Biotek), Signature Q100 (OLink).
Ex vivo Precision Cut Tumor Slices (in development).
Pharmacokinetics/ pharmacodynamics studies (biotherapies and immuno-therapeutics)
High-resolution mass spectrometry analyses in biological matrix (tumors, plasma) for investigating exposure-response relationships and determining optimal dosing and scheduling (model-informed precision dosing, MIPD, Data interpretation).
Supervised and unsupervised analysis of Omics data.